IQVIA HOLDINGS INC
IQVNYSETrading Snapshot
- Day Range
- $269.47 β $282.41
- 52-Week Range
- $154.50 β $284.50
- Volume (shares)
- 1,722,524
- Avg Volume (shares)
- β
- Shares Outstanding
- 164.6M
- Next Earnings
- 2027-02-03
Fundamentals Snapshot
- Annual Revenue
- $16.31B
- Last Q Revenue
- $4.43B
- P/E Ratio
- 33.5
- P/S Ratio
- 2.7x
- EPS (TTM)
- $8.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β4.9%
IQVIA HOLDINGS INC
IQVAbout IQVIA HOLDINGS INC
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI
Citizens Financial Group Inc. RI increased its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 67.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exch

What IQVIA (IQV) Said on Its Q3 Earnings Call
IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rat

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.

IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.

IQVIA Reports Third-Quarter 2026 Results
IQVIA Holdings Inc. (Γ’ΒΒIQVIAΓ’ΒΒ) (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the li

IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.